Skip to content
TrialScanner

NCT04462328

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Phase 1Active, not recruitingAZNCollaborator

Registry record

Lead sponsor
Washington University School of Medicine
Conditions
Primary Central Nervous System Lymphoma
Primary completion
Dec 31, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04462328 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04462328: Acalabrutinib and Durvalumab... | TrialScanner